MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) — Relievant Medsystems, an organization devoted to remodeling the prognosis and therapy of vertebrogenic low again ache, introduced at present that Cigna Healthcare, a well being advantages supplier for 19 million People, has established nationwide protection for the Intracept® Process. The protection went into impact on Thursday, June 15, and expands entry to the process, when clinically acceptable, to sufferers in all 50 states in addition to Washington D.C. and Puerto Rico.
“This constructive protection willpower from Cigna Healthcare, one of many nation’s main well being profit suppliers, is vastly impactful in growing affected person and doctor entry to our confirmed therapy for vertebrogenic ache,” stated Tyler Binney, President and CEO of Relievant Medsystems. “We stay up for additional educating payers on the medical advantages of the Intracept Process in offering vital and sturdy ache reduction, in addition to decreasing total healthcare utilization.”
The choice from Cigna Healthcare comes shortly after Palmetto GBA, a Medicare Administrative Contractor (MAC) masking Medicare sufferers in Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia, revealed a last Native Protection Dedication (LCD) for basivertebral nerve (BVN) ablation that expanded entry to greater than 5 million lined lives in March of 2023.
“The proof supporting the Intracept Process is obvious, from the huge portfolio of revealed medical proof to the life-changing outcomes I’ve witnessed in my observe,” stated Brian Durkin, DO, Division Chief, New York Backbone and Ache Specialists. “As consciousness of vertebrogenic ache continues to develop, increasing insurance coverage protection is important to assist the tens of millions of sufferers with this distinct situation obtain significant reduction.”
Of the 30 million folks within the U.S. with continual low again ache, 1 in 6 are more likely to have vertebrogenic ache, a definite sort of continual low again ache attributable to injury to vertebral endplates, the interface between the disc and the vertebral physique. Sufferers usually have ache in the course of their low again, which worsens once they bend over, sit for lengthy durations of time, or when they’re lively. A doctor can affirm a affected person’s ache is vertebrogenic by observing Modic modifications, a biomarker seen on customary MRI that signifies irritation on the vertebral endplate.
Greater than 10,000 sufferers have now been handled with Relievant Medsystems’ minimally invasive Intracept Process, the one FDA-cleared therapy for continual vertebrogenic low again ache. The identical-day outpatient process makes use of focused radiofrequency vitality to cease the BVN from transmitting ache indicators to the mind and takes roughly one hour to carry out.
Primarily based on current information, sufferers usually expertise minimal post-procedure discomfort and a fast restoration. The Intracept Process is supported by sturdy scientific proof, together with two Stage I randomized medical trials and information exhibiting enhancements are sustained greater than 5 years post-procedure.
About Relievant Medsystems
Relievant Medsystems is a commercial-stage medical gadget firm remodeling the prognosis and therapy of vertebrogenic ache, a type of Continual Low Again Ache (CLBP), with the Intracept Process – a novel, clinically confirmed and commercially accessible therapy designed to enhance the standard of life for tens of millions of indicated sufferers. For extra details about Relievant Medsystems and the Intracept Process, go to www.relievant.com.
Media Contact:
Shelli Lissick, Bellmont Companions
(651) 276-6922 | shelli@bellmontpartners.com
Investor Contact:
Marissa Bych, Gilmartin Group
(805) 305-1244 | marissa@gilmartinir.com
Discussion about this post